Pulmonary Cryptococcosis in the Setting of Tofacitinib Therapy for Psoriasis
August 2015 | Volume 14 | Issue 8 | Case Report | 901 | Copyright © 2015
Lucia Seminario-Vidal MD PhD, Wendy Cantrell DNP, and Boni E. Elewski MD
Department of Dermatology, University of Alabama at Birmingham, Birmingham, AL
Tofacitinib is a novel drug that inhibits the JAK-STAT signaling pathway. It has been approved for the treatment of psoriatic arthritis and it is under investigation for the treatment of psoriasis and other inflammatory disorders. We report a case of pulmonary cryptococcosis in an otherwise immunocompetent patient taking tofacitinib for psoriasis. We hypothesized that tofacitinib contributed to this infection through inhibition of cytokines required for differentiation of T cells and suppression of macrophage activation. As dermatologists begin to use this drug they should be aware of the potential for cryptococcocal infection, because delay of diagnosis may increase the risk of a life-threatening outcome.
J Drugs Dermatol. 2015;14(8):901-902.
Purchase Original Article
Purchase a single fully formatted PDF of the original manuscript as it was published in the JDD.
Download the original manuscript as it was published in the JDD.
Contact a member of the JDD Sales Team to request a quote or purchase bulk reprints, e-prints or international translation requests.
To get access to JDD's full-text articles and archives, upgrade here.
Save an unformatted copy of this article for on-screen viewing.
Print the full-text of article as it appears on the JDD site.→ proceed | ↑ close
A 65 year-old Caucasian man with severe plaque psoriasis and psoriatic arthritis presented with a ten week history of progressive nasal congestion, intermittent fever, non-productive cough, and dyspnea. He was receiving tofacitinib for 6 months as investigational treatment for psoriasis and was pleased with the medication because his skin was clear, and he had no joint pain. At initial presentation of his respiratory symptoms, he went to an urgent care facility, where he was diagnosed with presumed influenza and was treated with oseltamivir. Three weeks after, his symptoms had not improved. His primary care physician treated him with levofloxacin and fluticasone, as well as salmeterol inhalation powder for 10 days. Two weeks later, he was treated with ceftriaxone and prednisone 10 mg oral daily for 7 days. He reported worsening of his symptoms during the treatments. The patient was HIV negative, without history of immunodeficiency disorder, or malignancy. He had no history of tuberculosis exposure and a Quantiferon-TB Gold was negative prior to initiation of tofacitininb therapy. He denied smoking, drinking, using illicit drugs, or travelling.
On exam, he was in mild distress, with low-grade fever, and oxygen saturation of 93% on room air. His neck was not stiff, skin and joints were normal, and lung sounds were diminished on the right. Laboratory studies revealed normal serum chemistries and complete blood cell counts. Chest radiography demonstrated multifocal right-sided pneumonia. Serum cryptococcal antigen was positive, with a titer of 1:1024. No confirmatory fungal culture was obtained. A lumbar puncture was negative.
Tofacitinib was discontinued and he received oral fluconazole 400 mg daily for 6 months, showing a quick recovery. Cryptococcal serum titers were negative at the end of the treatment. Infectious disease recommended that he may restart a biologic while on prophylactic fluconazole 200 mg weekly. However, the patient refused biologic or systemic therapy for his psoriasis. His psoriasis has been treated with phototherapy achieving a partial control.
Infection with Cryptococcus usually results in harmless colonization of the airways. An effective immune response can eliminate the yeast or result in the formation of dormant yeasts within a pulmonary lymph node. If the cell-mediated immunity is defective, e.g., in patients receiving high dose glucorticoid therapy,1 dormant yeasts may reactivate causing pneumonia, meningitis, or disseminated disease. No reports have yet described an association of cryptococcosis with tofacitinib therapy for psoriasis.
Tofacitinib is a novel oral Janus kinase (JAK) inhibitor in development for the treatment of several inflammatory diseases. It has recently demonstrated efficacy and safety in phase 2 trials for moderate-to-severe plaque psoriasis.2 While no serious infections were observed in this study population, they were noted in patients with rheumatoid arthritis.3 In vitro and in vivo studies support a potential predisposition for fungal infections with tofacitinib therapy. It interferes with JAK-STAT signaling, blocking cytokines required for the differentiation of Th2 and Th1 cells,4 and suppresses the activation of blood-derived macrophages.5 Clinically, cryptoccocal pneumonia has been reported in one Australian patient with rheumatoid arthritis taking tofacitininb 10 mg twice a day and sulfasalazine 1 g twice